Sponsors

AstraZeneca is a leading global pharmaceutical company with an extensive product portfolio spanning six major therapeutic areas:gastrointestinal, cardiovascular, infection, neuroscience, oncology, and respiratory. AstraZeneca's Canadian headquarters and packaging facilities are located in Mississauga, Ontario, with a state-of-the-art drug discovery centre based in Montreal, Quebec. For more information, visit the company's website at www.astrazeneca.ca.

AstraZeneca est un chef de file mondial de l'industrie pharmaceutique, comme en témoigne son imposante gamme de médicaments dans six domaines thérapeutiques majeurs : gastro-entérologie, cardiologie, infectiologie, neurosciences, oncologie et pneumologie. Le siège social canadien d'AstraZeneca et les installations de conditionnement sont situés à Mississauga, en Ontario, et son centre ultramoderne de découverte de médicaments est à Montréal, au Québec. Pour de plus amples renseignements, visitez le site Web de la compagnie à www.astrazeneca.ca.



.
Janssen-Ortho Inc. has been servicing the Canadian healthcare industry for over 50 years. The company is an innovative research based pharmaceutical company located in Toronto, Ontario.

In 1995, Janssen-Ortho Inc was formed through the amalgamation of Janssen Pharmaceutica and Ortho-McNeil Inc, two members of the Johnson & Johnson worldwide family of companies.

This integration has created a vast resource dedicated to the advancement of better health and a better quality of life for all. This commitment is shared with our parent company, Johnson & Johnson, the largest healthcare company in the world.

At Merck Frosst, patients come first.  Merck Frosst Canada Ltd. is a research-driven pharmaceutical company.  Merck Frosst discovers, develops and markets a broad range of innovative medicines to improve human health.  The Merck Frosst Centre for Therapeutic Research, one of the largest biomedical research facilities in Canada, has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes and osteoporosis.    Merck Frosst is one of the top 20 R&D investors in Canada, with an investment of $117 million in 2005.  The Company is committed to fostering partnerships to deliver the most valuable health outcomes for Canadian patients. 

Merck Frosst is a recognized leader in the treatment of asthma, osteoporosis, HIV/AIDS, glaucoma, prostate disease, migraines and infectious diseases.  The Company also markets an extensive line of cardiovascular products for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines.  Based in Montréal, Quebec, Merck Frosst employs nearly 1,600 people including more than 300 of the world’s leading scientific personnel.  It is also firmly committed to science education and sponsors a number of programs designed to spark young people’s interest in science.  More information about Merck Frosst is available at http://www.merckfrosst.com.

Novo Nordisk is a healthcare company and a world leader in diabetes care and biopharmaceuticals.  Our aspiration is to defeat diabetes by finding better methods of diabetes prevention, detection and treatment.  In Canada, Novo Nordisk leads the insulin market with the widest range of products and services for diabetes care. 

Novo Nordisk, une société de soins de santé, est un chef de file mondial dans le traitement du diabète et les produits biopharmaceutiques. Nous aspirons à vaincre le diabète en élaborant des méthodes plus efficaces pour prévenir, dépister et traiter le diabète. Novo Nordisk domine le marché de l'insuline au Canada, en y offrant la plus vaste gamme de produits et de services consacrés au traitement du diabète.

www.novonordisk.ca